IGF1R and Graves ophthalmopathy: In the context of targeting fibroblasts, IGF-1R inhibitors have been extensively studied as therapeutic agents for autoimmune diseases, particularly active thyroid-associated ophthalmopathy (TAO) (Morshed et al., 2022; Kim et al., 2024; Mohyi and Smith, 2018).